ArticleJournal of the Royal College of Physicians of London1993
The economic implications of therapeutic conservatism.
Article in Journal of the Royal College of Physicians of London, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors affecting the uptake of new medicines: a systematic literature review.BMC health services research · 2014Pooled it
- Article
- Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.Frontiers in public health · 2018Review
- Variation over time in the association between polypharmacy and mortality in the older population.Drugs & aging · 2011Article
- Prescribing new drugs: qualitative study of influences on consultants and general practitioners.BMJ (Clinical research ed.) · 2001Article
- [Analysis of drug consumption with indicators of prescription quality].Atencion primaria · 2000Article
- Therapeutic substitution and therapeutic conservatism as cost-containment strategies in primary care: a study of fundholders and non-fundholders.The British journal of general practice : the journal of the Royal College of General Practitioners · 1999Article
- The need for pharmacoeconomic evaluations in the NHS.PharmacoEconomics · 1998Article
- Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.PharmacoEconomics · 1997Review
- An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996.PharmacoEconomics · 1996Review
- A UK national prescribing list?PharmacoEconomics · 1995Article
- Therapeutic conservatism: more costly in the long term? A UK perspective.PharmacoEconomics · 1995Article
- More therapeutic conservatism.Journal of the Royal College of Physicians of London · 1993Article
- Therapeutic conservatism.Journal of the Royal College of Physicians of London · 1993Article
- The growth of medical science: the lessons of Malthus.Journal of the Royal College of Physicians of LondonArticle
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We review the pattern of prescribing medicines in the United Kingdom (UK) and compare it with that in other European markets. The prescribing of medicines in Britain has always been more conservative than in other major European markets such as France, Italy, Germany, and Spain, but the difference is becoming more marked. The conservative nature of the British prescription medicine market is indicated by three international comparisons. First, British doctors prescribe fewer items per patient per year than their counterparts in other European countries. Second, they are less likely to prescribe a product containing a new active chemical entity (NCE) than their counterparts in other countries. This resistance to the use of newer medicines has increased over the past decade. Third, British doctors rely on a progressively smaller number of active substances for a greater proportion of their prescriptions. As a result of these trends the pharmaceutical industry--at least as far as its British sales are concerned--is becoming more dependent on the sales of older products and on the occasional 'blockbuster' to finance its research. Declining uptake of new medicines, coupled with increasing pressure on doctors to prescribe cheaper generics instead of branded medicines, reduces the ability of pharmaceutical companies to fund their investment in research into as yet unconquered diseases. This trend could work against the interests of both patients and the British economy.
Indexed as
Identifiers
8501666PMC5396627What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.